David Lucchino is the President and CEO of Brenig Therapeutics. David brings over two decades of extensive executive leadership experience to his current role. Throughout his career, he has been pivotal in the launch, growth, and operation of numerous successful companies within both the biotechnology and medical device sectors.

His experience spans a wide range of critical activities, including delivering meaningful returns to investors, securing regulatory approvals in the US and EU, navigating corporate mergers and acquisitions, leading a company through its IPO on the Nasdaq, championing patient advocacy, and chairing the largest global life sciences economic development organization.

Before leading Brenig Therapeutics, David co-founded Frequency Therapeutics with Professor Robert S. Langer of MIT and other co-founders. Their vision was to pioneer a new approach to regenerative medicine, with a primary focus on restoring hearing for the most common type of hearing loss. The company also pursued a second program aimed at remyelination in multiple sclerosis.

Prior to Frequency, David served as President and CEO of Entrega Bio, a biotechnology firm specializing in oral drug delivery technology. Earlier in his career, David co-founded Semprus BioSciences, again in collaboration with Dr. Langer. At Semprus, he spearheaded the FDA and European CE marketing clearance for a product designed to reduce infections and blood clotting, ultimately leading to the company's acquisition. His professional journey also includes a role at the investment firm Polaris Partners, and he began his career as a co-founder of LaunchCyte, LLC, a biotech investment firm backed by the University of Pittsburgh Medical Center that successfully created substantial shareholder value. 

David is the past Chairman of the Board of Directors of MassBio, serving during a period of unprecedented growth in the region's life science industry. During his chairmanship, he was appointed to the Governor of Massachusetts’ Economic Development Planning Council to represent the Life Science Industry. Furthermore, he was instrumental in establishing "Project Onramp," a groundbreaking program creating opportunities within local life science companies for students from underserved communities.

David currently serves on the board of directors of the Multiple Myeloma Research Foundation (MMRF). He was appointed by Governor Charlie Baker to the Massachusetts STEM (Science, Technology, Engineering, and Math) Advisory Council and is a distinguished member of the College of Fellows for the American Institute of Medical and Biological Engineering.

David holds a B.A. from Denison University, an M.S. from the Newhouse School of Journalism at Syracuse University, and an M.B.A. from the MIT Sloan School of Management as an Alfred P. Sloan Fellow.